{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:08:29Z","timestamp":1785553709785,"version":"3.56.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.jaad.2010.03.009","type":"journal-article","created":{"date-parts":[[2011,3,17]],"date-time":"2011-03-17T04:38:36Z","timestamp":1300336716000},"page":"671-681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study"],"prefix":"10.1016","volume":"64","author":[{"given":"Bruce E.","family":"Strober","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Poulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco A.","family":"Kerdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiraz R.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin M.","family":"Okun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2010.03.009_bib1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2010.03.009_bib2","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course","volume":"64","author":"Gladman","year":"2005","journal-title":"outcome. Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2010.03.009_bib3","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1365-2133.2006.07432.x","article-title":"Initial experience with routine administration of etanercept in psoriasis","volume":"155","author":"de Groot","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.03.009_bib4","first-page":"241","article-title":"Molecular differences in anticytokine therapies","volume":"21","author":"Calabrese","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2010.03.009_bib5","unstructured":"Ko H-S. Clinical trial design in psoriasis. Oral presentation at: 49th Meeting of the Dermatologic and Ophthalmologic Advisory Committee; March 20, 1998; Bethesda, MD."},{"key":"10.1016\/j.jaad.2010.03.009_bib6","unstructured":"Etanercept [package insert]. Immunex Corporation, Thousand Oaks, California. Issue date: 06\/05\/03."},{"issue":"Suppl","key":"10.1016\/j.jaad.2010.03.009_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","article-title":"European S3 guidelines on the systemic treatment of psoriasis vulgaris","volume":"23","author":"Pathirana","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2010.03.009_bib8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis: oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"10.1016\/j.jaad.2010.03.009_bib9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2010.03.009_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1477-7525-4-71","article-title":"The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study","volume":"4","author":"Shikiar","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jaad.2010.03.009_bib11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1365-2133.2008.08628.x","article-title":"Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis","volume":"159","author":"Strober","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.03.009_bib12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","volume":"107","author":"Pearson","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jaad.2010.03.009_bib13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.03.009_bib14","unstructured":"Baker D, Camacho-Martinez F, Gu Y, Okun MM. Adalimumab is efficacious in patients with moderate to severe psoriasis who had received or failed systemic therapies. Poster 2416 presented at: American Academy of Dermatology Summer Meeting; July 30\u2013August 3, 2008; Chicago, IL."},{"key":"10.1016\/j.jaad.2010.03.009_bib15","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"CHAMPION Study Investigators. Efficacy and safety\u00a0results from the comparative study of adalimumab vs methotrexate vs placebo in psoriasis patients (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.03.009_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jaad.2009.08.040","article-title":"Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept","volume":"63","author":"Bissonnette","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.03.009_bib17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jaad.2008.12.036","article-title":"Adalimumab treats psoriasis in patients previously treated with etanercept: a case series","volume":"61","author":"Yamauchi","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.03.009_bib18","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.clim.2009.01.002","article-title":"Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor","volume":"131","author":"Kaymakcalan","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaad.2010.03.009_bib19","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/ard.2008.092833","article-title":"Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis","volume":"68","author":"Radstake","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2010.03.009_bib20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2010.03.009_bib21","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/rheumatology\/kem091","article-title":"Research in Active Rheumatoid Arthritis (ReAct) Study Group. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice","volume":"46","author":"Bombardieri","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2010.03.009_bib22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jaad.2007.11.011","article-title":"The effect of weight on the efficacy of biologic therapy in patients with psoriasis","volume":"58","author":"Clark","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.03.009_bib23","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaad.2009.09.040","article-title":"Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis","volume":"63","author":"Menter","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.03.009_bib24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2174\/187152906779010719","article-title":"Vascular C-reactive protein in the pathogenesis of coronary artery disease: role of vascular inflammation and oxidative stress","volume":"6","author":"Inoue","year":"2006","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"10.1016\/j.jaad.2010.03.009_bib25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.atherosclerosis.2005.09.023","article-title":"C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003","volume":"187","author":"Boekholdt","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jaad.2010.03.009_bib26","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis: a randomized, controlled phase III trial","volume":"296","author":"Gelfand","year":"2006","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jaad.2010.03.009_bib27","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","article-title":"Prevalence of cardiovascular risk factors in patients with psoriasis","volume":"55","author":"Neimann","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.03.009_bib28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/09546630701646172","article-title":"Impact of adalimumab treatment on patient-reported outcomes: results from a phase III clinical trial in patients with moderate to severe plaque psoriasis","volume":"18","author":"Revicki","year":"2007","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2010.03.009_bib29","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2133.2007.08236.x","article-title":"Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis","volume":"158","author":"Revicki","year":"2008","journal-title":"Br J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962210003154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962210003154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:19:06Z","timestamp":1759270746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962210003154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0190962210003154"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2010.03.009","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2010.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}